Article citationsMore>>

Elias, D., Lefevre, J.H., Chevalier, J., Brouquet, A., Marchal, F., Classe, J.M., Ferron, G., Guilloit, J.M., Meeus, P., Goéré, D. and Bonastre, J. (2009) Complete Cytoreductive Surgery plus Intraperitoneal Chemohyperthermia with Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin. Journal of Clinical Oncology, 27, 681-685.
https://doi.org/10.1200/JCO.2008.19.7160

has been cited by the following article:

• TITLE: Outcome of Management of Pseudomyxoma Peritonei: National Cancer Institute Experience

  AUTHORS: Z. Gad, O. Nassar, H. Soliman, S. Mohamed, M. Mohamed

  KEYWORDS: HIPEC, NCI Experience, Pseudomyxoma Peritonii

  JOURNAL NAME: Journal of Cancer Therapy, Vol.9 No.4, April 27, 2018

  ABSTRACT: Background: The current treatment for pseudomyxoma peritonei (PMP) consists of radical cytoreductive surgery (CRS) followed by hyperthermic intra-peritoneal chemotherapy (HIPEC). Aim: To assess PMP patients regarding the clinical and pathological characteristics, the treatment including surgery (CRS) and chemotherapy either HIPEC type or post-operative systemic chemotherapy aiming to evaluate end results regarding recurrence and survival. Patients and Methods: This retrospective study included 39 patients with PMP who were diagnosed, treated and followed-up from 2009-2014 at National Cancer Institute, Cairo, Egypt. Results: High grade mucinous adenocarcinoma was found in 23.1% of patients. Patients with low grade tumor showed higher survival rate compared with patients with high grade disease. The mean operative PCI score (peritoneal cancer index) that was done to all patients who were explored was 15.81. Our study reported success to achieve complete cytoreduction that was combined with HIPEC in 44% of patients who were planned for this modality. Treatment related postoperative grade (3 - 5) complications mainly surgery related developed in 17.3 of patients. Operative mortality was 22.2%. The follow up period in our study was quite short (mean 22.9). However the overall survival at the end of the follow up in our study was 48.7%, 1 year survival was 82%, and 2 year survival was 41%. The overall survival in patients treated with CRS and HIPEC was 66.6%, with 1 year and 2 year survival of 91% and 66.6% respectively. Only 2 patients developed recurrent disease during the follow up period. Conclusions: The outcome of PMP treatment process is extremely variable. Combined CRS and HIPEC is considered the best therapeutic approach for patients with PMP. Surgical experience combined with proper patient selection have to be built up together to improve the outcome. That could only be achieved through more centralization of patients’ treatment in specialized units or center.